Shin Nippon Biomedical Laboratories Ltd - ESG Rating & Company Profile powered by AI
This webpage of Shin Nippon Biomedical Laboratories Ltd is assembled by All Street Sevva using leading Cognitive Robots. The SDG rating for Shin Nippon Biomedical Laboratories Ltd indicates its reporting of the United Nations Sustainable Development Goals. This webpage displays a zero-cost Environmental, Social and Governance analysis covering Shin Nippon Biomedical Laboratories Ltd.
Shin Nippon Biomedical Laboratories Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 4.8 and governance score of 1.6.
3.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1144 | Veerhealth Care Ltd | 3.6 | Medium |
1144 | iStreet Network Ltd | 3.6 | Medium |
1186 | Shin Nippon Biomedical Laboratories Ltd | 3.5 | Medium |
1186 | CRISPR Therapeutics AG | 3.5 | Medium |
1186 | Catalent Inc | 3.5 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Shin Nippon Biomedical Laboratories Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Shin Nippon Biomedical Laboratories Ltd disclose current and historical energy intensity?
Does Shin Nippon Biomedical Laboratories Ltd report the average age of the workforce?
Does Shin Nippon Biomedical Laboratories Ltd reference operational or capital allocation in relation to climate change?
Does Shin Nippon Biomedical Laboratories Ltd disclose its ethnicity pay gap?
Does Shin Nippon Biomedical Laboratories Ltd disclose cybersecurity risks?
Does Shin Nippon Biomedical Laboratories Ltd offer flexible work?
Does Shin Nippon Biomedical Laboratories Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Shin Nippon Biomedical Laboratories Ltd disclose the number of employees in R&D functions?
Does Shin Nippon Biomedical Laboratories Ltd conduct supply chain audits?
Does Shin Nippon Biomedical Laboratories Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Shin Nippon Biomedical Laboratories Ltd conduct 360 degree staff reviews?
Does Shin Nippon Biomedical Laboratories Ltd disclose the individual responsible for D&I?
Does Shin Nippon Biomedical Laboratories Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Shin Nippon Biomedical Laboratories Ltd disclose current and / or historical scope 2 emissions?
Does Shin Nippon Biomedical Laboratories Ltd disclose water use targets?
Does Shin Nippon Biomedical Laboratories Ltd have careers partnerships with academic institutions?
Did Shin Nippon Biomedical Laboratories Ltd have a product recall in the last two years?
Does Shin Nippon Biomedical Laboratories Ltd disclose incidents of discrimination?
Does Shin Nippon Biomedical Laboratories Ltd allow for Work Councils/Collective Agreements to be formed?
Has Shin Nippon Biomedical Laboratories Ltd issued a profit warning in the past 24 months?
Does Shin Nippon Biomedical Laboratories Ltd disclose parental leave metrics?
Does Shin Nippon Biomedical Laboratories Ltd disclose climate scenario or pathway analysis?
Does Shin Nippon Biomedical Laboratories Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Shin Nippon Biomedical Laboratories Ltd disclose the pay ratio of women to men?
Does Shin Nippon Biomedical Laboratories Ltd support suppliers with sustainability related research and development?
Does Shin Nippon Biomedical Laboratories Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Shin Nippon Biomedical Laboratories Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Shin Nippon Biomedical Laboratories Ltd involved in embryonic stem cell research?
Does Shin Nippon Biomedical Laboratories Ltd disclose GHG and Air Emissions intensity?
Does Shin Nippon Biomedical Laboratories Ltd disclose its waste policy?
Does Shin Nippon Biomedical Laboratories Ltd report according to TCFD requirements?
Does Shin Nippon Biomedical Laboratories Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Shin Nippon Biomedical Laboratories Ltd disclose energy use targets?
Does Shin Nippon Biomedical Laboratories Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Shin Nippon Biomedical Laboratories Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Shin Nippon Biomedical Laboratories Ltd
These potential risks are based on the size, segment and geographies of the company.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.